White Rose Research Online

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk
Universities of Leeds, Sheffield and York

Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/174707/

Version: Supplemental Material

---

**Article:**
Thomas, C., Mandrik, O., Saunders, C.L. et al. (2021) The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis. Cancer Prevention Research, 14 (8). pp. 811-822. ISSN: 1940-6207

https://doi.org/10.1158/1940-6207.capr-20-0620

---

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

UNIVERSITY OF LEEDS
University of Sheffield
UNIVERSITY of York

Supplementary Figure 1: Receiver Operating Curves and FIT starting age distribution (based on a mean starting age of 60) for each risk score, based on assessing 10-year risk at age 40.



Supplementary Figure 2: Incremental outcomes for risk-stratification (based on a mean screening start age of 50), compared to screening start age of 50 for the entire population using FIT120. Incremental net monetary benefit is based on a cost-effectiveness threshold of £20,000/QALY.



Supplementary Figure 3: Incremental outcomes for risk-stratification (based on a mean screening start age of 60), compared to screening start age of 60 for the entire population using FIT20. Incremental net monetary benefit is based on a cost-effectiveness threshold of £20,000/QALY.



Supplementary Table 1: Values used in the model for FIT sensitivity and specificity (first round of screening).

| FIT Threshold | Age | Sex | Sensitivity to CRC | Sensitivity to High Risk Adenoma | Sensitivity to Low Risk Adenoma | Specificity |
|---|---|---|---|---|---|---|
| FIT120 | 60 | Male | 0.354 | 0.104 | 0.020 | 0.996 |
| | | Female | 0.156 | 0.085 | 0.011 | 0.997 |
| | 50 | Male | 0.356 | 0.080 | 0.014 | 0.998 |
| | | Female | 0.144 | 0.074 | 0.008 | 0.998 |
| FIT20 | 60 | Male | 0.410 | 0.249 | 0.080 | 0.976 |
| | | Female | 0.211 | 0.229 | 0.049 | 0.979 |
| FIT Faecal Immunochemical Test; CRC Colorectal Cancer | | | | | | |

Supplementary Table 2: Full set of incremental outcomes for risk-stratification based on a mean FIT120 screening start age of 50, compared to screening everyone with FIT120 at age 50.

| Risk Score | | Ma | Jeon | MaJeon | Huyghe | Total Risk | Total Risk + Sex |
|---|---|---|---|---|---|---|---|
| **Total Costs per person** | M | £0.78 | -£0.34 | £3.46 | £2.35 | £3.15 | £3.82 |
| | *L* | *-£19* | *-£21* | *-£16* | *-£20* | *-£20* | *-£20* |
| | *U* | *£20* | *£19* | *£26* | *£26* | *£27* | *£27* |
| **CRC Treatment Costs per person** | M | £0.54 | -£0.49 | -£1.23 | -£1.87 | -£2.51 | -£2.38 |
| | *L* | *-£20* | *-£23* | *-£23* | *-£26* | *-£27* | *-£28* |
| | *U* | *£20* | *£20* | *£22* | *£21* | *£23* | *£23* |
| **Screen & Surveillance Costs per person** | M | £0.23 | £0.15 | £4.69 | £4.22 | £5.67 | £6.20 |
| | *L* | *-£5* | *-£5* | *-£1* | *-£1* | *£0* | *£0* |
| | *U* | *£5* | *£5* | *£10* | *£10* | *£12* | *£13* |
| **QALYs per person** | M | 0.0002 | 0.0001 | 0.0010 | 0.0018 | 0.0023 | 0.0025 |
| | *L* | *-0.0048* | *-0.0043* | *-0.0044* | *-0.0036* | *-0.0038* | *-0.0035* |
| | *U* | *0.0050* | *0.0045* | *0.0059* | *0.0075* | *0.0087* | *0.0090* |
| **NMB per person (£20,000/QALY Threshold)** | M | £3.53 | £2.48 | £16.91 | £33.15 | £42.79 | £46.32 |
| | *L* | *-£91* | *-£86* | *-£88* | *-£75* | *-£75* | *-£68* |
| | *U* | *£96* | *£90* | *£112* | *£140* | *£171* | *£180* |
| **NMB per person (£30,000/QALY Threshold)** | M | £5.68 | £3.55 | £27.10 | £50.90 | £65.76 | £71.38 |
| | *L* | *-£139* | *-£129* | *-£133* | *-£118* | *-£110* | *-£109* |
| | *U* | *£149* | *£136* | *£172* | *£209* | *£257* | *£269* |
| **MJC per person (£20,000/QALY Threshold)** | M | £4.98 | £3.50 | £23.86 | £46.76 | £60.36 | £65.33 |
| | *L* | *-£129* | *-£121* | *-£124* | *-£106* | *-£106* | *-£96* |
| | *U* | *£136* | *£127* | *£158* | *£198* | *£241* | *£253* |
| **MJC per person (£30,000/QALY Threshold)** | M | £8.01 | £5.00 | £38.23 | £71.80 | £92.76 | £100.69 |
| | *L* | *-£196* | *-£182* | *-£187* | *-£167* | *-£155* | *-£153* |
| | *U* | *£210* | *£192* | *£243* | *£295* | *£363* | *£380* |
| **Prob. cost-effective (£20,000/QALY)** | | 53% | 53% | 64% | 73% | 75% | 78% |
| **Prob. cost-effective (£30,000/QALY)** | | 53% | 52% | 66% | 74% | 75% | 78% |
| **CRC Incidence per 100,000 people** | M | 1 | -5 | -41 | -61 | -83 | -89 |
| | *L* | *-1106* | *-1098* | *-1201* | *-1242* | *-1324* | *-1363* |
| | *U* | *1092* | *1050* | *1082* | *1121* | *1157* | *1165* |
| **CRC Mortality per 100,000 people** | M | -4 | 0 | -28 | -44 | -64 | -70 |
| | *L* | *-483* | *-462* | *-518* | *-560* | *-616* | *-611* |
| | *U* | *460* | *458* | *450* | *456* | *471* | *460* |
| **FIT screening invites per person** | M | -0.035 | -0.031 | 0.572 | 0.044 | 0.012 | 0.035 |
| | *L* | *-0.058* | *-0.055* | *0.546* | *0.006* | *-0.091* | *-0.072* |
| | *U* | *-0.012* | *-0.008* | *0.596* | *0.082* | *0.093* | *0.125* |
| **Screening colonoscopies per 100,000 people** | M | -28 | -26 | 188 | 237 | 360 | 403 |
| | *L* | *-785* | *-782* | *-485* | *-517* | *-458* | *-362* |
| | *U* | *723* | *728* | *916* | *1019* | *1206* | *1272* |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.

Supplementary Table 3: Full set of incremental outcomes for risk-stratification based on a mean FIT20 screening start age of 60, compared to screening everyone with FIT20 at age 60.

| Risk Score | | Ma | Jeon | MaJeon | Huyghe | Total Risk | Total Risk + Sex |
|---|---|---|---|---|---|---|---|
| **Total Costs per person** | M | -£1.96 | -£2.07 | -£2.08 | -£3.15 | -£3.29 | -£2.13 |
| | *L* | *-£23* | *-£20* | *-£23* | *-£26* | *-£25* | *-£26* |
| | *U* | *£17* | *£15* | *£16* | *£18* | *£20* | *£21* |
| **CRC Treatment Costs per person** | M | -£2.78 | -£2.67 | -£7.46 | -£14.36 | -£20.08 | -£20.48 |
| | *L* | *-£24* | *-£22* | *-£30* | *-£40* | *-£44* | *-£47* |
| | *U* | *£17* | *£16* | *£12* | *£8* | *£4* | *£5* |
| **Screen & Surveillance Costs per person** | M | £0.82 | £0.60 | £5.37 | £11.22 | £16.79 | £18.36 |
| | *L* | *-£5* | *-£5* | *£0* | *£5* | *£9* | *£11* |
| | *U* | *£6* | *£6* | *£12* | *£18* | *£25* | *£28* |
| **QALYs per person** | M | 0.0001 | 0.0003 | 0.0013 | 0.0038 | 0.0055 | 0.0058 |
| | *L* | *-0.0043* | *-0.0037* | *-0.0029* | *-0.0007* | *0.0004* | *0.0007* |
| | *U* | *0.0041* | *0.0041* | *0.0057* | *0.0091* | *0.0113* | *0.0118* |
| **NMB per person (£20,000/QALY Threshold)** | M | £3.77 | £8.36 | £28.10 | £79.03 | £113.32 | £118.45 |
| | *L* | *-£78* | *-£73* | *-£57* | *-£14* | *£11* | *£20* |
| | *U* | *£86* | *£86* | *£117* | *£181* | *£225* | *£233* |
| **NMB per person (£30,000/QALY Threshold)** | M | £4.68 | £11.50 | £41.11 | £116.97 | £168.33 | £176.60 |
| | *L* | *-£120* | *-£109* | *-£87* | *-£17* | *£16* | *£30* |
| | *U* | *£127* | *£126* | *£172* | *£271* | *£336* | *£357* |
| **MJC per person (£20,000/QALY Threshold)** | M | £5.32 | £11.79 | £39.64 | £111.48 | £159.85 | £167.08 |
| | *L* | *-£110* | *-£103* | *-£81* | *-£20* | *£16* | *£28* |
| | *U* | *£121* | *£121* | *£165* | *£256* | *£317* | *£329* |
| **MJC per person (£30,000/QALY Threshold)** | M | £6.59 | £16.22 | £58.00 | £165.00 | £237.45 | £249.12 |
| | *L* | *-£169* | *-£154* | *-£123* | *-£24* | *£22* | *£43* |
| | *U* | *£179* | *£177* | *£243* | *£382* | *£474* | *£503* |
| **Prob. cost-effective (£20,000/QALY)** | | 54% | 57% | 74% | 95% | 99% | 99% |
| **Prob. cost-effective (£30,000/QALY)** | | 53% | 57% | 74% | 94% | 99% | 98% |
| **CRC Incidence per 100,000 people** | M | 20 | -3 | -75 | -212 | -335 | -347 |
| | *L* | *-1147* | *-1104* | *-1271* | *-1445* | *-1614* | *-1605* |
| | *U* | *1210* | *1145* | *1090* | *984* | *923* | *886* |
| **CRC Mortality per 100,000 people** | M | 34 | 10 | -21 | -106 | -182 | -193 |
| | *L* | *-480* | *-469* | *-536* | *-622* | *-709* | *-733* |
| | *U* | *582* | *524* | *500* | *420* | *351* | *328* |
| **FIT screening invites per person** | M | 0.016 | -0.024 | 0.253 | 0.020 | 0.027 | 0.049 |
| | *L* | *-0.011* | *-0.050* | *0.224* | *-0.022* | *-0.040* | *-0.018* |
| | *U* | *0.043* | *0.002* | *0.283* | *0.061* | *0.088* | *0.112* |
| **Screening colonoscopies per 100,000 people** | M | -457 | -274 | 119 | 526 | 1166 | 1397 |
| | *L* | *-1536* | *-1339* | *-1006* | *-762* | *-107* | *137* |
| | *U* | *718* | *858* | *1302* | *1798* | *2448* | *2722* |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.

Supplementary Table 4: Full set of incremental outcomes for a scenario in which screening uptake is reduced by 25%. Risk-stratification based on a mean FIT120 screening start age of 60 is compared to screening everyone with FIT120 at age 60.

| Risk Score | | Ma | Jeon | MaJeon | Huyghe | Total Risk | Total Risk + Sex |
|---|---|---|---|---|---|---|---|
| **Total Costs per person** | M | -£1.97 | -£1.82 | -£1.24 | -£0.03 | £2.00 | £2.52 |
| | *L* | *-£17* | *-£17* | *-£16* | *-£16* | *-£16* | *-£15* |
| | *U* | *£13* | *£13* | *£14* | *£16* | *£20* | *£22* |
| **CRC Treatment Costs per person** | M | -£2.11 | -£1.58 | -£2.44 | -£4.91 | -£5.38 | -£5.69 |
| | *L* | *-£18* | *-£17* | *-£18* | *-£22* | *-£24* | *-£25* |
| | *U* | *£14* | *£14* | *£13* | *£12* | *£13* | *£14* |
| **Screen & Surveillance Costs per person** | M | £0.14 | -£0.24 | £1.19 | £4.88 | £7.38 | £8.21 |
| | *L* | *-£3* | *-£4* | *-£2* | *£1* | *£3* | *£4* |
| | *U* | *£4* | *£3* | *£5* | *£9* | *£12* | *£14* |
| **QALYs per person** | M | 0.0000 | 0.0001 | 0.0004 | 0.0019 | 0.0028 | 0.0031 |
| | *L* | *-0.0033* | *-0.0031* | *-0.0030* | *-0.0017* | *-0.0011* | *-0.0008* |
| | *U* | *0.0033* | *0.0033* | *0.0038* | *0.0060* | *0.0077* | *0.0078* |
| **NMB per person (£20,000/QALY Threshold)** | M | £1.33 | £3.80 | £9.74 | £37.75 | £54.60 | £59.20 |
| | *L* | *-£61* | *-£55* | *-£56* | *-£31* | *-£21* | *-£14* |
| | *U* | *£68* | *£68* | *£77* | *£119* | *£146* | *£150* |
| **NMB per person (£30,000/QALY Threshold)** | M | £1.01 | £4.78 | £13.98 | £56.61 | £82.90 | £90.06 |
| | *L* | *-£91* | *-£86* | *-£82* | *-£50* | *-£31* | *-£20* |
| | *U* | *£101* | *£102* | *£115* | *£179* | *£224* | *£232* |
| **MJC per person (£20,000/QALY Threshold)** | M | £1.87 | £5.36 | £13.73 | £53.25 | £77.02 | £83.51 |
| | *L* | *-£86* | *-£77* | *-£79* | *-£43* | *-£29* | *-£19* |
| | *U* | *£95* | *£96* | *£109* | *£168* | *£206* | *£211* |
| **MJC per person (£30,000/QALY Threshold)** | M | £1.42 | £6.75 | £19.72 | £79.85 | £116.94 | £127.04 |
| | *L* | *-£128* | *-£122* | *-£116* | *-£70* | *-£43* | *-£28* |
| | *U* | *£142* | *£144* | *£162* | *£252* | *£315* | *£327* |
| **Prob. cost-effective (£20,000/QALY)** | | 50% | 54% | 61% | 86% | 93% | 93% |
| **Prob. cost-effective (£30,000/QALY)** | | 50% | 54% | 61% | 87% | 93% | 93% |
| **CRC Incidence per 100,000 people** | M | 6 | 3 | -13 | -102 | -147 | -163 |
| | *L* | *-978* | *-932* | *-1010* | *-1121* | *-1236* | *-1228* |
| | *U* | *995* | *971* | *979* | *895* | *909* | *877* |
| **CRC Mortality per 100,000 people** | M | 30 | 21 | 12 | -56 | -102 | -115 |
| | *L* | *-405* | *-394* | *-411* | *-498* | *-553* | *-579* |
| | *U* | *458* | *426* | *438* | *384* | *329* | *344* |
| **FIT screening invites per person** | M | -0.176 | -0.221 | -0.160 | -0.139 | -0.115 | -0.081 |
| | *L* | *-0.200* | *-0.239* | *-0.186* | *-0.173* | *-0.177* | *-0.146* |
| | *U* | *-0.154* | *-0.200* | *-0.132* | *-0.103* | *-0.053* | *-0.020* |
| **Screening colonoscopies per 100,000 people** | M | -229 | -200 | -134 | 228 | 489 | 601 |
| | *L* | *-807* | *-779* | *-725* | *-412* | *-187* | *-55* |
| | *U* | *365* | *357* | *473* | *933* | *1161* | *1289* |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.

Supplementary Table 5: Incremental cost-effectiveness outcomes for risk-stratification based on a mean FIT120 screening start age of 60, compared to screening everyone with FIT120 at age 60, using a discount rate of 1.5%. Note that clinical and resource use outcomes are not discounted so are identical to those shown in Table 2 of the main results.

| **Risk Score** | | **Ma** | **Jeon** | **MaJeon** | **Huyghe** | **Total Risk** | **Total Risk + Sex** |
|---|---|---|---|---|---|---|---|
| **Total Costs per person** | M | -£1.42 | -£1.24 | -£0.68 | £1.24 | £3.00 | £3.64 |
| | *L* | *-£11* | *-£11* | *-£10* | *-£9* | *-£9* | *-£8* |
| | *U* | *£8* | *£8* | *£9* | *£12* | *£15* | *£16* |
| **CRC Treatment Costs per person** | M | -£1.79 | -£1.27 | -£2.01 | -£3.26 | -£3.73 | -£3.82 |
| | *L* | *-£12* | *-£11* | *-£12* | *-£14* | *-£16* | *-£16* |
| | *U* | *£8* | *£9* | *£8* | *£8* | *£9* | *£8* |
| **Screen & Surveillance Costs per person** | M | £0.37 | £0.03 | £1.33 | £4.51 | £6.72 | £7.46 |
| | *L* | *-£2* | *-£2* | *-£1* | *£2* | *£3* | *£4* |
| | *U* | *£3* | *£2* | *£4* | *£8* | *£10* | *£12* |
| **QALYs per person** | M | 0.0000 | 0.0001 | 0.0003 | 0.0013 | 0.0020 | 0.0022 |
| | *L* | *-0.0018* | *-0.0016* | *-0.0015* | *-0.0007* | *-0.0002* | *-0.0003* |
| | *U* | *0.0019* | *0.0019* | *0.0023* | *0.0037* | *0.0048* | *0.0048* |
| **NMB per person (£20,000/QALY Threshold)** | M | £1.01 | £2.70 | £7.00 | £25.31 | £36.62 | £39.69 |
| | *L* | *-£33* | *-£30* | *-£29* | *-£16* | *-£9* | *-£5* |
| | *U* | *£39* | *£37* | *£49* | *£69* | *£91* | *£91* |
| **NMB per person (£30,000/QALY Threshold)** | M | £0.81 | £3.42 | £10.16 | £38.59 | £56.43 | £61.36 |
| | *L* | *-£49* | *-£45* | *-£42* | *-£23* | *-£10* | *-£6* |
| | *U* | *£58* | *£53* | *£71* | *£106* | *£140* | *£139* |
| **MJC per person (£20,000/QALY Threshold)** | M | £1.65 | £4.39 | £11.41 | £41.23 | £59.66 | £64.66 |
| | *L* | *-£54* | *-£49* | *-£47* | *-£27* | *-£15* | *-£9* |
| | *U* | *£63* | *£61* | *£79* | *£112* | *£148* | *£148* |
| **MJC per person (£30,000/QALY Threshold)** | M | £1.32 | £5.58 | £16.56 | £62.85 | £91.93 | £99.95 |
| | *L* | *-£80* | *-£74* | *-£68* | *-£38* | *-£16* | *-£10* |
| | *U* | *£94* | *£87* | *£115* | *£173* | *£229* | *£226* |
| **Prob cost-effective (£20,000/QALY)** | | 50% | 56% | 63% | 88% | 95% | 95% |
| **Prob cost-effective (£30,000/QALY)** | | 49% | 56% | 62% | 88% | 95% | 95% |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.

Supplementary Table 6: Incremental cost-effectiveness outcomes for risk-stratification based on a mean FIT120 screening start age of 60, compared to screening everyone with FIT120 at age 60, using a discount rate of 5%. Note that clinical and resource use outcomes are not discounted so are identical to those shown in Table 2 of the main results.

| **Risk Score** | | **Ma** | **Jeon** | **MaJeon** | **Huyghe** | **Total Risk** | **Total Risk + Sex** |
|---|---|---|---|---|---|---|---|
| **Total Costs per person** | M | -£8.19 | -£6.54 | -£8.18 | -£10.16 | -£10.08 | -£9.52 |
| | *L* | *-£45* | *-£45* | *-£47* | *-£48* | *-£54* | *-£51* |
| | *U* | *£29* | *£33* | *£31* | *£29* | *£34* | *£33* |
| **CRC Treatment Costs per person** | M | -£6.68 | -£4.86 | -£9.05 | -£18.98 | -£24.27 | -£25.77 |
| | *L* | *-£46* | *-£46* | *-£51* | *-£59* | *-£70* | *-£68* |
| | *U* | *£33* | *£35* | *£33* | *£24* | *£22* | *£19* |
| **Screen & Surveillance Costs per person** | M | -£1.51 | -£1.68 | £0.87 | £8.82 | £14.19 | £16.25 |
| | *L* | *-£11* | *-£11* | *-£9* | *-£1* | *£3* | *£5* |
| | *U* | *£8* | *£7* | *£10* | *£20* | *£27* | *£29* |
| **QALYs per person** | M | -0.0007 | 0.0000 | 0.0009 | 0.0058 | 0.0087 | 0.0096 |
| | *L* | *-0.0098* | *-0.0094* | *-0.0091* | *-0.0048* | *-0.0026* | *-0.0022* |
| | *U* | *0.0097* | *0.0097* | *0.0114* | *0.0169* | *0.0212* | *0.0222* |
| **NMB per person (£20,000/QALY Threshold)** | M | -£6.23 | £6.07 | £26.30 | £125.93 | £184.21 | £202.11 |
| | *L* | *-£190* | *-£179* | *-£166* | *-£84* | *-£47* | *-£22* |
| | *U* | *£196* | *£199* | *£233* | *£345* | *£424* | *£452* |
| **NMB per person (£30,000/QALY Threshold)** | M | -£13.44 | £5.83 | £35.36 | £183.81 | £271.27 | £298.41 |
| | *L* | *-£290* | *-£272* | *-£255* | *-£132* | *-£68* | *-£52* |
| | *U* | *£296* | *£301* | *£344* | *£517* | *£639* | *£675* |
| **MJC per person (£20,000/QALY Threshold)** | M | -£7.23 | £7.04 | £30.52 | £146.14 | £213.78 | £234.56 |
| | *L* | *-£220* | *-£208* | *-£193* | *-£97* | *-£55* | *-£26* |
| | *U* | *£227* | *£231* | *£271* | *£400* | *£492* | *£525* |
| **MJC per person (£30,000/QALY Threshold)** | M | -£15.59 | £6.76 | £41.04 | £213.32 | £314.82 | £346.31 |
| | *L* | *-£336* | *-£316* | *-£296* | *-£153* | *-£79* | *-£60* |
| | *U* | *£344* | *£350* | *£399* | *£600* | *£742* | *£783* |
| **Prob cost-effective (£20,000/QALY)** | | 46% | 53% | 57% | 87% | 95% | 95% |
| **Prob cost-effective (£30,000/QALY)** | | 45% | 52% | 56% | 86% | 95% | 95% |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.

Supplementary Table 7: Full set of incremental outcomes by sex for risk-stratification based on a mean FIT120 screening start age of 60, compared to screening everyone with FIT120 at age 60.

| Risk Score | | Ma | Jeon | MaJeon | Huyghe | Total Risk | Total Risk + Sex |
|---|---|---|---|---|---|---|---|
| **Males** | | | | | | | |
| **Total Costs per person** | M | -£3.40 | -£3.23 | -£2.76 | -£0.42 | £1.59 | £6.31 |
| | *L* | *-£33* | *-£31* | *-£32* | *-£31* | *-£33* | *-£30* |
| | *U* | *£25* | *£23* | *£28* | *£31* | *£39* | *£40* |
| **CRC Treatment Costs per person** | M | -£4.47 | -£2.84 | -£5.57 | -£7.94 | -£10.87 | -£11.96 |
| | *L* | *-£34* | *-£32* | *-£35* | *-£42* | *-£49* | *-£52* |
| | *U* | *£24* | *£25* | *£26* | *£27* | *£26* | *£26* |
| **Screen & Surveillance Costs per person** | M | £1.07 | -£0.39 | £2.81 | £7.53 | £12.46 | £18.27 |
| | *L* | *-£6* | *-£7* | *-£4* | *£0* | *£3* | *£8* |
| | *U* | *£8* | *£7* | *£10* | *£17* | *£23* | *£30* |
| **QALYs per person** | M | 0.0002 | 0.0000 | 0.0009 | 0.0029 | 0.0047 | 0.0061 |
| | *L* | *-0.0060* | *-0.0055* | *-0.0048* | *-0.0037* | *-0.0026* | *-0.0016* |
| | *U* | *0.0062* | *0.0062* | *0.0077* | *0.0101* | *0.0134* | *0.0152* |
| **NMB per person (£20,000/QALY Threshold)** | M | £7.32 | £4.03 | £20.01 | £59.22 | £91.56 | £114.95 |
| | *L* | *-£115* | *-£107* | *-£92* | *-£66* | *-£53* | *-£31* |
| | *U* | *£132* | *£118* | *£149* | *£205* | *£262* | *£302* |
| **NMB per person (£30,000/QALY Threshold)** | M | £9.27 | £4.42 | £28.64 | £88.62 | £138.14 | £175.58 |
| | *L* | *-£174* | *-£158* | *-£141* | *-£99* | *-£82* | *-£45* |
| | *U* | *£197* | *£179* | *£218* | *£304* | *£391* | *£456* |
| **MJC per person (£20,000/QALY Threshold)** | M | M | £5.68 | £28.23 | £83.53 | £129.16 | £162.15 |
| | *L* | *-£162* | *-£151* | *-£130* | *-£94* | *-£74* | *-£43* |
| | *U* | *£186* | *£166* | *£210* | *£289* | *£370* | *£427* |
| **MJC per person (£30,000/QALY Threshold)** | M | £13.08 | £6.24 | £40.39 | £125.01 | £194.86 | £247.67 |
| | *L* | *-£245* | *-£223* | *-£198* | *-£140* | *-£115* | *-£63* |
| | *U* | *£278* | *£253* | *£307* | *£429* | *£552* | *£643* |
| **CRC Incidence per 100,000 people** | M | -3 | 19 | -29 | -132 | -229 | -321 |
| | *L* | *-1878* | *-1758* | *-1879* | *-2021* | *-2175* | *-2310* |
| | *U* | *1867* | *1837* | *1878* | *1728* | *1734* | *1625* |
| **CRC Mortality per 100,000 people** | M | 44 | 41 | 20 | -65 | -134 | -219 |
| | *L* | *-707* | *-685* | *-754* | *-808* | *-945* | *-1039* |
| | *U* | *849* | *788* | *822* | *697* | *639* | *555* |
| **FIT screening invites per person** | M | -0.008 | -0.203 | 0.019 | -0.121 | 0.008 | 0.930 |
| | *L* | *-0.049* | *-0.263* | *-0.040* | *-0.226* | *-0.150* | *0.771* |
| | *U* | *0.032* | *-0.151* | *0.076* | *-0.002* | *0.166* | *1.085* |
| **Screening colonoscopies per 100,000 people** | M | -334 | -345 | -170 | 317 | 820 | 1455 |
| | *L* | *-1543* | *-1577* | *-1308* | *-873* | *-413* | *50* |
| | *U* | *920* | *856* | *1141* | *1565* | *2226* | *2856* |
| **Females** | | | | | | | |
| **Total Costs per person** | M | £0.45 | £0.41 | £0.17 | -£2.85 | £1.36 | -£1.11 |
| | *L* | *-£21* | *-£18* | *-£20* | *£6* | *-£20* | *-£23* |
| | *U* | *£20* | *£19* | *£19* | *£7* | *£23* | *£21* |
| **CRC Treatment Costs per person** | M | £0.09 | -£0.68 | -£1.31 | -£4.91 | -£6.37 | -£5.29 |
| | *L* | *-£22* | *-£21* | *-£22* | *-£28* | *-£29* | *-£28* |
| | *U* | *£21* | *£18* | *£18* | *£18* | *£17* | *£18* |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Screen & Surveillance Costs per person** | M | £0.36 | £1.09 | £1.48 | £6.15 | £7.73 | £4.18 |
| | *L* | *-£4* | *-£3* | *-£3* | *£1* | *£2* | *-£1* |
| | *U* | *£5* | *£5* | *£6* | *£12* | *£14* | *£10* |
| **QALYs per person** | M | 0.0000 | 0.0003 | 0.0005 | 0.0024 | 0.0031 | 0.0024 |
| | *L* | *-0.0042* | *-0.0042* | *-0.0045* | *-0.0027* | *-0.0019* | *-0.0029* |
| | *U* | *0.0042* | *0.0049* | *0.0058* | *0.0082* | *0.0093* | *0.0084* |
| **NMB per person (£20,000/QALY Threshold)** | M | £0.34 | £5.90 | £9.94 | £45.79 | £60.22 | £49.59 |
| | *L* | *-£84* | *-£77* | *-£87* | *-£46* | *-£36* | *-£48* |
| | *U* | *£81* | *£92* | *£109* | *£158* | *£182* | *£169* |
| **NMB per person (£30,000/QALY Threshold)** | M | £0.74 | £9.05 | £15.00 | £69.30 | £91.01 | £73.83 |
| | *L* | *-£125* | *-£119* | *-£130* | *-£71* | *-£51* | *-£73* |
| | *U* | *£124* | *£141* | *£163* | *£237* | *£279* | *£250* |
| **MJC per person (£20,000/QALY Threshold)** | M | £0.48 | £8.32 | £14.03 | £64.59 | £84.95 | £69.95 |
| | *L* | *-£119* | *-£109* | *-£123* | *-£65* | *-£50* | *-£68* |
| | *U* | *£115* | *£129* | *£153* | *£223* | *£257* | *£239* |
| **MJC per person (£30,000/QALY Threshold)** | M | £1.04 | £12.76 | £21.16 | £97.75 | £128.38 | £104.14 |
| | *L* | *-£177* | *-£167* | *-£184* | *-£101* | *-£72* | *-£103* |
| | *U* | *£174* | *£199* | *£230* | *£334* | *£394* | *£353* |
| **CRC Incidence per 100,000 people** | M | 7 | -21 | -28 | -137 | -183 | -123 |
| | *L* | *-1228* | *-1281* | *-1267* | *-1436* | *-1522* | *-1497* |
| | *U* | *1205* | *1220* | *1252* | *1202* | *1196* | *1254* |
| **CRC Mortality per 100,000 people** | M | -7 | -21 | -25 | -108 | -145 | -98 |
| | *L* | *-559* | *-575* | *-600* | *-712* | *-774* | *-731* |
| | *U* | *546* | *535* | *569* | *492* | *468* | *542* |
| **FIT screening invites per person** | M | 0.039 | 0.146 | 0.049 | 0.186 | 0.094 | -0.721 |
| | *L* | *0.014* | *0.095* | *-0.002* | *0.082* | *-0.080* | *-0.891* |
| | *U* | *0.064* | *0.192* | *0.101* | *0.282* | *0.262* | *-0.551* |
| **Screening colonoscopies per 100,000 people** | M | -8 | 126 | 87 | 493 | 642 | 303 |
| | *L* | *-795* | *-648* | *-776* | *-310* | *-194* | *-476* |
| | *U* | *778* | *895* | *893* | *1383* | *1490* | *1148* |

QALY Quality Adjusted Life Year; NMB Net Monetary Benefit; MJC Maximum Justifiable Cost (of risk scoring procedure); CRC Colorectal Cancer; FIT Faecal Immunochemical Test; Prob. Probability; M Mean; L Lower 95% credible interval; U Upper 95% credible interval.